The Fetal Safety of Hydrocortisone-Pramoxine (Proctofoam-HC) for the Treatment of Hemorrhoids in Late Pregnancy

Neda Ebrahimi, S. Vohra, Christelle Gedeon, Hani Akoury, Paul S. Bernstein, Nicholas Pairaudeau, Johanne Cormier, Lorraine Dontigny, Marc-Yvon Arsenault, Claude Fortin,

Journal of Obstetrics and Gynaecology Canada · 2011 · 22 citations · 16 references

DOIFull text

Open access

Concepts

Abstract

OBJECTIVE: Fetal safety has never been studied for any drug used in the treatment of hemorrhoids. Proctofoam-HC is a combination of a corticosteroid and a local anaesthetic that is proven effective for the treatment of hemorrhoids. The objective of this study was to assess prospectively the fetal safety of third trimester exposure to Proctofoam-HC. METHODS: In a multicentre study, 204 [corrected] women exposed to Proctofoam-HC in the third trimester and a similar number of control pregnant women were followed up postnatally. RESULTS: When compared to controls exposure to Proctofoam-HC was not associated with any adverse fetal effects on birth weight, gestational age, rates of prematurity, or pre- or postnatal complications. CONCLUSION: Proctofoam-HC is safe to use in the treatment of hemorrhoids in late pregnancy.

References

16